Jennifer Cain Birkmose
MHS, MBA
VP, EUROPE STRATEGIC PARTNERSHIPS
Basel, Switzerland
Everything can be taken from a man but one thing: the last of the human freedoms – to choose one's attitude in any given set of circumstances" Viktor Frankl
Areas of Expertise
Access
Pricing
RWE
HEOR
European HTA
Patient Advocacy
Health PolicyManagement Consulting
Strategy Consulting
BD&L
Organizational design
Go to market / Launch
Access Negotiations
People Leadership
Board leadership
Biography
Jennifer Cain Birkmose is a seasoned executive with over 20 years of experience in the healthcare and pharmaceutical industries. Jennifer has a proven track record in Innovative pharmaceuticals, biotech, public private development partnerships, health policy, patient advocacy, board leadership and entrepreneurship. Jennifer started her career with the World Bank and WHO and further expanded to senior market access leadership roles in companies like Janssen, Novartis, Roche and SOBI. Jennifer is a board member of the Medicines for Malaria Venture.
Key accomplishments
2 time Tedx Speaker
Consultant to the Romanian Ministry of Health on drug pricing and HTA system reform 2023-2025
Lead the multi-stakeholder consultation to create the Women’s Centric Cancer Care discussion paper, 2023
Consulted the UN Secretary General, AARP white paper on digital health access for Senior Citizens 2022
Lead the EunetHTA joint action review for Alecensa, resulted in increased speed to access across the EU from 3 to 36 months 20, 2018
Architect of the Novartis Emerging Market Brand, leading to launch of core innovative launches into emerging markets within 12 months of a launch in the US, 2015
Supported the Ministry of Health of Russia in creating their core reimbursement system for treating rare and life threatening conditions
Key accomplishments
Joana E. Matos1, Jens Panse* 1, Tarek Mnif 2, Kerri Lehrhaupt1, Sujata P. Sarda3, Scott B. Baver3, Jesse Fishman3, Zalmai Hakimi4, Jameel Nazir4, Emmelie Persson4, Jennifer C. Birkmose, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA’S HUMANISTIC AND ECONOMIC BURDEN IN PATIENTS RECEIVING C5 INHIBITORS IN EUROPE. European Hematology Association (EHA) June 2021
Angsar Hebborn, Andre Oberdiek, Jennifer Cain Birkmose, Marlene Gyldmark. OP163 European Network for Health Technology Assessment Joint Action 3 Relative Effectiveness Pilots: Pharma Company Experience January 2018 International Journal of Technology Assessment in Health Care 34(S1):59-60DOI:10.1017/S026646231800168X,
Raja Shankar, Jennifer Cain Birkmose, Sheau-Tyng, Maggie Lee, Role Of Patient Financial Contributions In Improving Patient Access To Medicine. Abstract and poster accepted ISPOR 2013. (New Orleans)
Raja Shankar, Jennifer Cain Birkmose, Sheau-Tyng, Maggie Lee Guidling Principles for Effective Private Health Insurance in Emerging Markets. Abstract and poster accepted, ISPOR 2013. (Buenos Aires)
Raja Shankar, Stacey Hickson, Jennifer Cain, Guiding Principles for Providing Effective Access to Medicines in Emerging Markets. Abstract accepted, ISPOR 2012. (Berlin)
E.Lyubov et al, Riserpidone long-acting injection (RLAI) in the treatment of schizophrenia : 3 month preliminary results from the electronic schizophrenia treatment adherence registry (E-STAR) in Russia. Abstract accepted, ISPOR 2008.
Grosse Tebbe et. al, Health Systems in Transition Profile, The Former Yugoslav Republic of Macedonia, European Observatory on Health Care Systems, Copenhagen, 2006.
Figueras, J, McKee M, Cain J, Lessof S.(eds) (2004) Health systems in transition: learning from experience. European Observatory on Health Systems and Policies, Occasional Series Number 1. WHO Europe.
Jakubowski E., Cain J. Health Systems Decentralization in Bosnia and Herzegovina, Euro Observer Volume 5, No. 1, 2003. Cain, J., Serbia and Montenegro, what lies ahead for the new Union?, Euro Observer, Volume 4 No. 3, 2002
Cain et. al in Cain, J. Jakubowski (eds), Health Systems in Transition Profile, Bosnia and Herzegovina, European Observatory on Health Care Systems, Copenhagen, 2002.
Education
MHS, Johns Hopkins Bloomberg School of Public Health
MBA, Solvay Business School
Harvard Negotiation Project Training
My letter
The only thing that is certain is life is change. I use the DELTA letter to remind myself that we are changing, evolving and growing every day. From the turn over of cells, the testing of our strength and resilience, to the growth that comes from the hard earned wisdom of life: without embracing change, we fall behind or even perish. In my mission to serve our clients at Aesara, I am guided by the letter DELTA to guide me to transform, change and shape a world that brings better outcomes, access and advocacy for patients and healthcare systems.
